BRPI1005322A2 - anticorpo, composição farmacêutica e uso de pelo menos um anticorpo - Google Patents

anticorpo, composição farmacêutica e uso de pelo menos um anticorpo

Info

Publication number: BRPI1005322A2
Authority: BR; Brazil
Prior art keywords: antibody; pharmaceutical composition; pharmaceutical; composition
Prior art date: 2009-01-21

Application number

BRPI1005322A

Other languages

English (en)

Inventor

Didierlaurent Denis

Kadouche Jean

Chose Olivier

Original Assignee

Inst Nat Sante Rech Med

Monoclonal Antibodies Therapeutics

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-01-21

Filing date

2010-01-21

Publication date

2019-09-24

2010-01-21 Application filed by Inst Nat Sante Rech Med, Monoclonal Antibodies Therapeutics filed Critical Inst Nat Sante Rech Med

2019-09-24 Publication of BRPI1005322A2 publication Critical patent/BRPI1005322A2/pt

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Immunology (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Biochemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Rheumatology (AREA)
Transplantation (AREA)
Pain & Pain Management (AREA)
Dermatology (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Orthopedic Medicine & Surgery (AREA)
Ophthalmology & Optometry (AREA)
Physical Education & Sports Medicine (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Microbiology (AREA)
Mycology (AREA)
Epidemiology (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

BRPI1005322A 2009-01-21 2010-01-21 anticorpo, composição farmacêutica e uso de pelo menos um anticorpo BRPI1005322A2 (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP09305057A EP2210903A1 (en)	2009-01-21	2009-01-21	Anti-CD160 monoclonal antibodies and uses thereof
PCT/EP2010/050694 WO2010084158A1 (en)	2009-01-21	2010-01-21	Anti-cd 160 monoclonal antibodies and uses thereof

Publications (1)

Publication Number	Publication Date
BRPI1005322A2 true BRPI1005322A2 (pt)	2019-09-24

Family

ID=40651612

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI1005322A BRPI1005322A2 (pt)	2009-01-21	2010-01-21	anticorpo, composição farmacêutica e uso de pelo menos um anticorpo

Country Status (9)

Country	Link
US (1)	US20110280866A1 (pt)
EP (2)	EP2210903A1 (pt)
JP (1)	JP2012515746A (pt)
KR (1)	KR20110119720A (pt)
CN (1)	CN102317318A (pt)
AU (1)	AU2010207710A1 (pt)
BR (1)	BRPI1005322A2 (pt)
CA (1)	CA2750444A1 (pt)
WO (1)	WO2010084158A1 (pt)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NZ759969A (en)	2013-12-20	2022-12-23	Fred Hutchinson Cancer Center	Tagged chimeric effector molecules and receptors thereof
EP3288570A4 (en)	2015-04-29	2018-11-21	Fred Hutchinson Cancer Research Center	Modified stem cells and uses thereof
PE20181326A1 (es)	2015-11-03	2018-08-20	Janssen Biotech Inc	Anticuerpos que se unen especificamente a pd-1 y sus usos
CN109996868A (zh)	2016-09-23	2019-07-09	弗雷德哈钦森癌症研究中心	特异性用于次要组织相容性(h)抗原ha-1的tcr及其用途
CA3080270A1 (en) *	2016-10-25	2018-05-03	Inserm (Institut National De La Sante Et De La Recherche Medicale)	Monoclonal antibodies binding to the cd160 transmembrane isoform
FR3061716B1 (fr) *	2017-01-06	2019-05-17	Elsalys Biotech	Nouveaux composes ciblant le cd160 humain
JP7037577B2 (ja)	2017-03-15	2022-03-16	フレッドハッチンソンキャンサーリサーチセンター	高親和性ｍａｇｅ－ａ１特異的ｔｃｒ及びその使用
CA3063563A1 (en)	2017-05-24	2018-11-29	Effector Therapeutics, Inc.	Compositions and methods for an improved antitumor immune response
US12398191B2 (en)	2017-08-11	2025-08-26	Fred Hutchinson Cancer Center	BRAF-specific TCRs and uses thereof
CN111051349A (zh)	2017-09-06	2020-04-21	弗雷德哈钦森癌症研究中心	Strep-tag特异性嵌合受体及其用途
EP3678689A1 (en)	2017-09-06	2020-07-15	Fred Hutchinson Cancer Research Center	Strep-tag specific binding proteins and uses thereof
US12350312B2 (en)	2017-09-06	2025-07-08	Fred Hutchinson Cancer Center	Methods for improving adoptive cell therapy
US20210069241A1 (en)	2017-10-20	2021-03-11	Fred Hutchinson Cancer Research Center	Compositions and methods of immunotherapy targeting tigit and/or cd112r or comprising cd226 overexpression
US20220267403A1 (en)	2017-12-01	2022-08-25	Fred Hutchinson Cancer Research Center	Binding proteins specific for 5t4 and uses thereof
WO2019140278A1 (en)	2018-01-11	2019-07-18	Fred Hutchinson Cancer Research Center	Immunotherapy targeting core binding factor antigens
US12398209B2 (en)	2018-01-22	2025-08-26	Janssen Biotech, Inc.	Methods of treating cancers with antagonistic anti-PD-1 antibodies
AU2019218397A1 (en)	2018-02-12	2020-10-01	Fred Hutchinson Cancer Center	Cyclin A1 specific T cell receptors and uses thereof
AU2019224051A1 (en)	2018-02-26	2020-09-03	Fred Hutchinson Cancer Center	Compositions and methods for cellular immunotherapy
WO2019178539A1 (en) *	2018-03-16	2019-09-19	Ngm Biopharmaceuticals, Inc.	Bispecific antibodies
EP3802604A1 (en)	2018-05-31	2021-04-14	Glyconex Inc.	Therapeutic antibodies binding to biantennary lewis b and lewis y antigens
WO2020018964A1 (en)	2018-07-20	2020-01-23	Fred Hutchinson Cancer Research Center	Compositions and methods for controlled expression of antigen-specific receptors
CN112912387A (zh)	2018-08-22	2021-06-04	弗雷德哈钦森癌症研究中心	靶向kras或her2抗原的免疫疗法
US20240165232A1 (en)	2018-09-24	2024-05-23	Fred Hutchinson Cancer Research Center	Chimeric receptor proteins and uses thereof
CA3119188A1 (en)	2018-11-09	2020-05-14	Fred Hutchinson Cancer Research Center	T cell receptors specific for mesothelin and their use in immunotherapy
FI3898668T3 (fi)	2018-12-19	2023-11-28	Humabs Biomed Sa	B-hepatiittivirusta neutraloivia vasta-aineita ja niiden käyttöjä
KR20210108978A (ko)	2018-12-21	2021-09-03	오제 이뮈노테라프틱스	이작용성 항-pd-1/il-7 분자
WO2020165374A1 (en)	2019-02-14	2020-08-20	Ose Immunotherapeutics	Bifunctional molecule comprising il-15ra
CN114026116A (zh)	2019-02-20	2022-02-08	弗雷德哈钦森癌症研究中心	Ras新抗原特异性结合蛋白及其用途
WO2020185796A1 (en)	2019-03-11	2020-09-17	Fred Hutchinson Cancer Research Center	High avidity wt1 t cell receptors and uses thereof
JP7737978B2 (ja)	2019-08-20	2025-09-11	フレッドハッチンソンキャンサーセンター	Ｗｔ－１に特異的なｔ細胞免疫療法
CA3152511A1 (en)	2019-08-29	2021-03-04	Vir Biotechnology, Inc.	Antibody compositions and methods for treating hepatitis b virus infection
WO2021122866A1 (en)	2019-12-17	2021-06-24	Ose Immunotherapeutics	Bifunctional molecules comprising an il-7 variant
PH12022553569A1 (en)	2020-06-24	2023-04-12	Humabs Biomed Sa	Engineered hepatitis b virus neutralizing antibodies and uses thereof
CN116724053A (zh)	2020-09-24	2023-09-08	弗雷德哈钦森癌症中心	靶向sox2抗原的免疫治疗
WO2022066973A1 (en)	2020-09-24	2022-03-31	Fred Hutchinson Cancer Research Center	Immunotherapy targeting pbk or oip5 antigens
WO2022076353A1 (en)	2020-10-06	2022-04-14	Fred Hutchinson Cancer Research Center	Compositions and methods for treating mage-a1-expressing disease
WO2022132836A2 (en)	2020-12-14	2022-06-23	Fred Hutchinson Cancer Research Center	Compositions and methods for cellular immunotherapy
JP2024504167A (ja)	2021-01-26	2024-01-30	ヴィア・バイオテクノロジー・インコーポレイテッド	Ｂ型肝炎ウイルス感染を処置するための抗体組成物および方法
MX2023011964A (es)	2021-04-09	2024-01-08	Ose Immunotherapeutics	Nuevo andamio para moléculas bifuncionales con propiedades mejoradas.
EP4320156A1 (en)	2021-04-09	2024-02-14	Ose Immunotherapeutics	Scaffold for bifunctioanl molecules comprising pd-1 or cd28 and sirp binding domains
TW202317602A (zh)	2021-07-15	2023-05-01	福瑞德哈金森腫瘤中心	嵌合多肽
WO2023215725A1 (en)	2022-05-02	2023-11-09	Fred Hutchinson Cancer Center	Compositions and methods for cellular immunotherapy
TW202411246A (zh)	2022-05-23	2024-03-16	美商維爾生物科技股份有限公司	經工程化之b型肝炎病毒中和抗體及其用途
JP2025525886A (ja)	2022-08-02	2025-08-07	オーエスイー・イミュノセラピューティクス	Ｃｄ２８に対する多機能性分子
CN120435302A (zh)	2023-01-09	2025-08-05	普罗塔拉治疗公司	化脓性链球菌非活细胞与免疫检查点抑制剂联合治疗三阴性乳腺癌和非肌层浸润性膀胱癌
WO2025081123A1 (en)	2023-10-12	2025-04-17	Fred Hutchinson Cancer Center	Methods and compositions for improving t cell immunotherapy
WO2025101820A1 (en)	2023-11-08	2025-05-15	Fred Hutchinson Cancer Center	Compositions and methods for cellular immunotherapy
WO2025149667A1 (en)	2024-01-12	2025-07-17	Pheon Therapeutics Ltd	Antibody drug conjugates and uses thereof
WO2025245169A1 (en)	2024-05-21	2025-11-27	Fred Hutchinson Cancer Center	Immunotherapy cells equipped with a collagen-targeting payload
US12551514B1 (en)	2025-07-25	2026-02-17	Protara Therapeutics, Inc.	Combination of non-viable cells of Streptococcus pyogenes and immune checkpoint inhibitor for the treatment of triple negative breast cancer and non-muscle invasive bladder cancer

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CU22545A1 (es) *	1994-11-18	1999-03-31	Centro Inmunologia Molecular	Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
US5225539A (en)	1986-03-27	1993-07-06	Medical Research Council	Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en)	1986-03-27	1986-04-30	Winter G P	Recombinant dna product
AU625613B2 (en) *	1988-01-05	1992-07-16	Novartis Ag	Novel chimeric antibodies
US5530101A (en)	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
WO1991008303A1 (fr) *	1989-11-28	1991-06-13	Teijin Limited	Anticorps contre l'activateur de plasminogene tissulaire bicatenaire humain
FR2828403B1 (fr)	2001-08-07	2003-10-17	Abtech	Utilisation de molecules solubles hla de classe 1 pour la preparation de compositions pharmaceutiques utiles pour inhiber l'angiogenese
EP1626059A1 (en) *	2004-08-09	2006-02-15	Institut National De La Sante Et De La Recherche Medicale (Inserm)	Angiogenic and immunologic applications of anti-CD160 specific compounds obtainable from mAb CL1-R2
CA2600929A1 (en)	2005-03-04	2006-09-14	Biogen Idec Ma Inc.	Methods of humanizing immunoglobulin variable regions through rational modification of complementarity determining residues

2009
- 2009-01-21 EP EP09305057A patent/EP2210903A1/en not_active Withdrawn
2010
- 2010-01-21 AU AU2010207710A patent/AU2010207710A1/en not_active Abandoned
- 2010-01-21 US US13/145,509 patent/US20110280866A1/en not_active Abandoned
- 2010-01-21 KR KR1020117019343A patent/KR20110119720A/ko not_active Withdrawn
- 2010-01-21 BR BRPI1005322A patent/BRPI1005322A2/pt not_active IP Right Cessation
- 2010-01-21 CA CA2750444A patent/CA2750444A1/en not_active Abandoned
- 2010-01-21 JP JP2011546790A patent/JP2012515746A/ja active Pending
- 2010-01-21 EP EP10701011A patent/EP2389393A1/en not_active Withdrawn
- 2010-01-21 CN CN2010800050829A patent/CN102317318A/zh active Pending
- 2010-01-21 WO PCT/EP2010/050694 patent/WO2010084158A1/en not_active Ceased

Also Published As

Publication number	Publication date
KR20110119720A (ko)	2011-11-02
EP2210903A1 (en)	2010-07-28
JP2012515746A (ja)	2012-07-12
CA2750444A1 (en)	2010-07-29
WO2010084158A1 (en)	2010-07-29
AU2010207710A1 (en)	2011-08-25
EP2389393A1 (en)	2011-11-30
CN102317318A (zh)	2012-01-11
US20110280866A1 (en)	2011-11-17

Legal Events

Date	Code	Title	Description
2019-10-01	B08F	Application fees: application dismissed [chapter 8.6 patent gazette]
2020-01-21	B08K	Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]	Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

Publication	Publication Date	Title
BRPI1005322A2 (pt)	2019-09-24	anticorpo, composição farmacêutica e uso de pelo menos um anticorpo
BRPI0917315A2 (pt)	2015-11-17	anticorpo, composicao farmaceutico, e, uso de uma composicao farmaceutica
BRPI0915137A2 (pt)	2016-02-16	uso de pelo menos um composto, peptídeo, e, formulação farmacêutica
BR112012002331A2 (pt)	2019-09-24	composição antiviral, composição farmacêutica e uso de quantidade efetiva de composição farmacêutica
BRPI1007018A2 (pt)	2016-03-29	composto, composição farmacêutica, e , uso de um composto.
BRPI1016219A2 (pt)	2016-04-26	composto, composição farmacêutica, e, uso de um composto
BRPI1008793A2 (pt)	2016-03-08	composto, uso de um composto, e, composição farmacêutica
BRPI0915136A2 (pt)	2019-09-24	uso de pelo menos um composto, peptídeo, e, formulação farmacêutica
BR112012004335A2 (pt)	2015-09-08	composto, composição farmacêutica, e, uso do composto.
BRPI1008906A2 (pt)	2016-03-15	composto, composição farmacêutica, e, uso de um composto.
BRPI0912717A2 (pt)	2014-12-23	Composição farmacêutica, e, uso de 5-azacitidina
BRPI0919942A2 (pt)	2014-12-23	Composto, composição farmacêutica, e, uso de um composto
BRPI0907562A2 (pt)	2017-05-23	composto, composição farmacêutica, e, uso de um composto
BRPI0921375A2 (pt)	2015-12-29	composto, composição farmacêutica, e, uso de um composto
BR112013011448A2 (pt)	2016-08-09	composto, composição farnmacêutica, e, uso do composto
BRPI0821115A2 (pt)	2015-06-16	Composto derivado de aminotriazol, medicamento, composição farmacêutica e uso do composto
BRPI0917579A2 (pt)	2016-10-11	composto, composição farmacêutica, métodos, e, uso de um composto
BR112013008259A2 (pt)	2017-12-12	composto, composição farmacêutica, e, uso de um composto
BR112013015397A2 (pt)	2016-09-20	composto, composição farmacêutica, e, uso de um composto
BRPI1010621A2 (pt)	2016-06-21	derivado de imidazoquinolinonas, sua composição farmacêutica e seu uso
BRPI0921879A2 (pt)	2018-10-16	composto, composição farmacêutica , e, uso de um composto
BRPI1009757A2 (pt)	2016-03-15	composto, composição farmacêutica, e , uso de um composto.
BRPI0906937A2 (pt)	2016-04-19	composto, composição farmacêutica, e, uso de um composto
BRPI0915473A2 (pt)	2015-11-10	composto, composição farmacêutica, e, uso de um composto
BRPI1007186A2 (pt)	2016-02-23	composto, composição farmacêutica, e, uso de um composto